CA2280097A1 - Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer - Google Patents
Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer Download PDFInfo
- Publication number
- CA2280097A1 CA2280097A1 CA002280097A CA2280097A CA2280097A1 CA 2280097 A1 CA2280097 A1 CA 2280097A1 CA 002280097 A CA002280097 A CA 002280097A CA 2280097 A CA2280097 A CA 2280097A CA 2280097 A1 CA2280097 A1 CA 2280097A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cancer
- altered
- pten
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 107
- 201000011510 cancer Diseases 0.000 title claims abstract description 56
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 238000003745 diagnosis Methods 0.000 title claims description 10
- 108700025695 Suppressor Genes Proteins 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 50
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 38
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims abstract description 31
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 230000035772 mutation Effects 0.000 claims description 103
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 83
- 238000012217 deletion Methods 0.000 claims description 70
- 230000037430 deletion Effects 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 48
- 201000002847 Cowden syndrome Diseases 0.000 claims description 46
- 208000012609 Cowden disease Diseases 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000000481 breast Anatomy 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 16
- 108700024394 Exon Proteins 0.000 claims description 15
- 101150073900 PTEN gene Proteins 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000019502 Thymic epithelial neoplasm Diseases 0.000 abstract description 55
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 abstract description 55
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 68
- 208000005017 glioblastoma Diseases 0.000 description 51
- 108020004705 Codon Proteins 0.000 description 33
- 230000004075 alteration Effects 0.000 description 26
- 210000000349 chromosome Anatomy 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 238000012163 sequencing technique Methods 0.000 description 19
- 206010006187 Breast cancer Diseases 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 108700028369 Alleles Proteins 0.000 description 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 14
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 13
- 235000002374 tyrosine Nutrition 0.000 description 13
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- 108091035242 Sequence-tagged site Proteins 0.000 description 12
- 102100024547 Tensin-1 Human genes 0.000 description 12
- 108010088950 Tensins Proteins 0.000 description 12
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 12
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
- 206010018338 Glioma Diseases 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- 108020004485 Nonsense Codon Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 9
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 9
- 230000037433 frameshift Effects 0.000 description 9
- 230000037434 nonsense mutation Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 8
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 8
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 7
- 208000002927 Hamartoma Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 108010013534 Auxilins Proteins 0.000 description 6
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100023922 Putative tyrosine-protein phosphatase auxilin Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000008121 dextrose Substances 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 5
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 5
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 5
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 5
- 108091060211 Expressed sequence tag Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108091008819 oncoproteins Proteins 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 102000003910 Cyclin D Human genes 0.000 description 4
- 108090000259 Cyclin D Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- 102100025734 Dual specificity protein phosphatase CDC14A Human genes 0.000 description 4
- 101000932600 Homo sapiens Dual specificity protein phosphatase CDC14A Proteins 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000001650 focal adhesion Anatomy 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000005748 tumor development Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QKYZQKJXAKNEPA-UHFFFAOYSA-N 3-hydroxy-5-methyl-1-phenylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1N(O)C(=O)C=2C(C)=CSC=2N1C1=CC=CC=C1 QKYZQKJXAKNEPA-UHFFFAOYSA-N 0.000 description 3
- 101800000504 3C-like protease Proteins 0.000 description 3
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 206010050183 Macrocephaly Diseases 0.000 description 3
- 208000005767 Megalencephaly Diseases 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 208000036878 aneuploidy Diseases 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 101800000607 p15 Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000011317 telomere syndrome Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000000225 tumor suppressor protein Substances 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 2
- 230000003322 aneuploid effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000030878 follicular thyroid adenoma Diseases 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000037442 genomic alteration Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000010700 sporadic breast cancer Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000610550 Homo sapiens Opiorphin prepropeptide Proteins 0.000 description 1
- 101001087045 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 101001002066 Homo sapiens Pleiotropic regulator 1 Proteins 0.000 description 1
- 101000830696 Homo sapiens Protein tyrosine phosphatase type IVA 1 Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100024599 Protein tyrosine phosphatase type IVA 1 Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 101000804877 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 5'-3' exoribonuclease 1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 201000009741 thyroid Hurthle cell carcinoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un acide nucléique codant pour le gène P-TEN ou pour une forme modifiée de celui-ci. L'invention concerne également un gène P-TEN purifié ou une forme modifiée de celui-ci. L'invention concerne en outre les gènes P-TEN décrits, dans lesquels P-TEN possède un domaine phosphatase modifié, tronqué ou supprimé. De plus, l'invention concerne un procédé permettant de diagnostiquer un cancer chez un patient, qui comporte l'étape consistant à détecter la présence, dans un échantillon approprié provenant du patient, d'une forme modifiée de P-TEN ou d'un acide nucléique codant pour une forme modifiée de P-TEN. D'autre part, l'invention concerne un procédé permettant d'identifier un composé chimique pouvant être utile comme médicament pour le traitement de cancer, ce procédé comportant les étapes consistant à tester des composés pour rechercher des effets d'une activité de P-TEN, et à identifier des composés présentant un tel effet.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3694397P | 1997-02-07 | 1997-02-07 | |
| US60/036,943 | 1997-02-07 | ||
| PCT/US1998/002615 WO1998034624A1 (fr) | 1997-02-07 | 1998-02-06 | Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2280097A1 true CA2280097A1 (fr) | 1998-08-13 |
Family
ID=21891553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002280097A Abandoned CA2280097A1 (fr) | 1997-02-07 | 1998-02-06 | Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1023076A4 (fr) |
| AU (1) | AU6653698A (fr) |
| CA (1) | CA2280097A1 (fr) |
| WO (1) | WO1998034624A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287854B1 (en) | 1996-10-22 | 2001-09-11 | Imperial Cancer Research Technology Limited | Diagnosis of susceptibility to cancer and treatment thereof |
| WO1999002704A2 (fr) * | 1997-07-08 | 1999-01-21 | Cold Spring Harbor Laboratory | Phosphatase a double specificite et procedes d'utilisation |
| AU6513701A (en) * | 2000-05-30 | 2001-12-11 | Advanced Res & Tech Inst | Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways |
| WO2004074459A2 (fr) * | 2003-02-19 | 2004-09-02 | Georgetown University | Cellules deficientes en pten et utilisations de celles-ci |
| CN109022461B (zh) * | 2017-06-08 | 2022-01-14 | 中山大学附属第一医院 | 一种PTEN基因的上游开放阅读框45aa-uORF核苷酸序列及其编码的多肽的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262242B1 (en) * | 1997-01-30 | 2001-07-17 | Board Of Regents, The University Of Texas System | Tumor suppressor designated TS10Q23.3 |
-
1998
- 1998-02-06 EP EP98908523A patent/EP1023076A4/fr not_active Withdrawn
- 1998-02-06 WO PCT/US1998/002615 patent/WO1998034624A1/fr not_active Application Discontinuation
- 1998-02-06 CA CA002280097A patent/CA2280097A1/fr not_active Abandoned
- 1998-02-06 AU AU66536/98A patent/AU6653698A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU6653698A (en) | 1998-08-26 |
| WO1998034624A1 (fr) | 1998-08-13 |
| EP1023076A1 (fr) | 2000-08-02 |
| EP1023076A4 (fr) | 2001-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ichimura et al. | Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades | |
| Kawamura et al. | Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia | |
| Forgacs et al. | Mutation analysis of the PTEN/MMAC1 gene in lung cancer | |
| US9216172B2 (en) | Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene | |
| US6090566A (en) | Diagnostic method detecting loss of wild-type p53 | |
| Smith et al. | Large common fragile site genes and cancer | |
| Elisei et al. | Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas | |
| JP5861244B2 (ja) | 新規ｒｏｓ１融合体の検出法 | |
| US6800617B1 (en) | Methods for restoring wild-type p53 gene function | |
| JPH08504081A (ja) | 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬 | |
| JPS63119698A (ja) | 網膜芽腫の診断用ベクタ− | |
| JPH044898A (ja) | 野生型ｐ５３遺伝子の欠失の検出 | |
| Saenko et al. | Novel tumorigenic rearrangement, Δrfp/ret, in a papillary thyroid carcinoma from externally irradiated patient | |
| Sekido et al. | Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines | |
| Tikoo et al. | p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13. 3 that is reportedly deleted in some gliomas | |
| CN111088365B (zh) | 一种用于检测甲状腺癌ret基因突变及融合的引物及试剂盒 | |
| Diccianni et al. | Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions | |
| WO2001066719A1 (fr) | Nouveau gene clone en neuroblastome humain et nouveaux fragments de gene | |
| Poi et al. | Somatic INK4a‐ARF locus mutations: A significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck | |
| WO1999028459A1 (fr) | Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1 | |
| Behn et al. | Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based" enriched PCR" technique. | |
| WO2001044466A1 (fr) | Gène d'oxydoréductase associé au site fragile fra16d | |
| US20220275450A1 (en) | Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence | |
| CA2280097A1 (fr) | Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer | |
| US20050130146A1 (en) | Histone deacetylase 9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |